Here's a link:

http://www.dailypolitical.com/finance/stock-market/mannkind-corp-given-new-8-00-price-target-at-mlv-capital-mnkd.htm

MannKind Corp. Given New $8.00 Price Target at MLV Capital (MNKD)

MLV Capital upped their price target on shares of MannKind Corp. (NASDAQ: MNKD) from $6.00 to $8.00 in a research note issued on Thursday, AnalystRatings.Net reports. The firm currently has a “buy” rating on the stock. MLV Capital’s price objective indicates a potential upside of 24.22% from the stock’s previous close.

MannKind Corp. (NASDAQ: MNKD) opened at 6.44 on Thursday. MannKind Corp. has a 1-year low of $1.57 and a 1-year high of $4.50. The stock’s 50-day moving average is currently $3.. The company’s market cap is $1.806 billion.

MannKind Corp. (NASDAQ: MNKD) last released its earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.15). Analysts expect that MannKind Corp. will post $-0.48 EPS for the current fiscal year.

MNKD has been the subject of a number of other recent research reports. Analysts at Piper Jaffray set a $8.40 price target on shares of MannKind Corp. in a research note to investors on Wednesday. Separately, analysts at Brinson Patrick initiated coverage on shares of MannKind Corp. in a research note to investors on Friday, June 21st. They set an “outperform” rating on the stock. Finally, analysts at Merrill Lynch downgraded shares of MannKind Corp. from a “buy” rating to a “neutral” rating in a research note to investors on Friday, June 7th.

Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $7.29.

MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.